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Abstract: Ilamycins/rufomycins and cyclomarins are marine cycloheptapeptides containing unusual
amino acids. Produced by Streptomyces sp., these compounds show potent activity against a range of
mycobacteria, including multidrug-resistant strains of Mycobacterium tuberculosis. The cyclomarins are
also very potent inhibitors of Plasmodium falciparum. Biosynthetically the cyclopeptides are obtained
via a heptamodular nonribosomal peptide synthetase (NRPS) that directly incorporates some of
the nonproteinogenic amino acids. A wide range of derivatives can be obtained by fermentation,
while bioengineering also allows the mutasynthesis of derivatives, especially cyclomarins. Other
derivatives are accessible by semisynthesis or total syntheses, reported for both natural product
classes. The anti-tuberculosis (anti-TB) activity results from the binding of the peptides to the N-
terminal domain (NTD) of the bacterial protease-associated unfoldase ClpC1, causing cell death by
the uncontrolled proteolytic activity of this enzyme. Diadenosine triphosphate hydrolase (PfAp3Aase)
was found to be the active target of the cyclomarins in Plasmodia. SAR studies with natural and
synthetic derivatives on ilamycins/rufomycins and cyclomarins indicate which parts of the molecules
can be simplified or otherwise modified without losing activity for either target. This review examines
all aspects of the research conducted in the syntheses of these interesting cyclopeptides.
Keywords: ilamycins; rufomycins; cyclomarins; tuberculosis; malaria; cyclopeptides; biosynthesis;
total synthesis; natural products
1. Introduction
Marine organisms produce a wealth of natural products, creating a universe of fas-
cinating new chemical structures [1,2]. These natural products are often the result of an
evolutionary process providing competitive advantages to their producers in their natural
environments. Therefore, many of these natural products have notable biological activities,
making them good candidates for drug development [3–5], including against infectious
diseases such as malaria and tuberculosis.
Malaria is one of the most common tropical diseases, with more than 200 million
infections and 600,000 deaths annually worldwide [6], mainly in the poorest population.
Tuberculosis (TB) is also common: in 2019, approximately 10 million people fell ill with the
disease and 1.5 million died [7]. In addition, in 2018, 500,000 people demonstrated resis-
tance to rifampicin, the most effective first-line drug, 80% of whom suffer from multidrug-
resistant tuberculosis (MDR-TB). The development of antibiotic resistance is widespread,
and these multi-resistant pathogens are a particularly serious problem. Therefore, new
drugs are required [8]. Most first- and second-line drugs were discovered or developed
between 1940 and 1980, often with a similar mode of action, facilitating the development of
resistance [9,10]. Modern drugs should therefore work via new modes of action against not
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only the MDR-TB strains but also the largely drug-resistant tuberculosis (XDR-TB) strains,
which are now almost resistant to all drugs. In addition, any new drug should effectively
destroy dormant bacteria, beneficial for short-term therapies, and be nontoxic (because of
the generally long treatment times required). Natural products are excellent candidates for
developing anti-TB drugs, and more than 60% of drugs under current development are
natural products or derived from natural products [11–13].
2. Discovery of Anti-Tubercular Cycloheptapeptides
2.1. Discovery of the Ilamycins/Rufomycins
In 1962, two independent research groups investigated marine Streptomycetes from soil
samples found on Japanese islands. Takita et al. observed that the culture filtrate of a new
strain, Streptomyces insulates (A-165-Z1), later renamed Streptomyces islandicus, inhibited the
growth of Mycobacterium 607 and Mycobacterium phlei. They isolated two antibiotics and
named them ilamycin A and B (IlaA and IlaB) [14,15].
In addition, at this time Shibata et al. isolated two new antibiotics, rufomycin I and
II (Ruf I and Ruf II), from the newly discovered Streptomyces atratus (46408), found to be
especially active against acid-fast bacteria [16,17]. The compounds were also active against
Mycobacterium tuberculosis and Mycobacterium smegmatis but almost inactive against most
other bacteria, fungi, and yeasts. Subsequent research indicated that these two antibiotics
possess very similar chemical structures [18–23].
The structures of ilamycins/rufomycins (Figure 1) are unusual, as these cyclic hep-
tapeptides contain a series of atypical amino acids. Most prominent is the N-prenylated
tryptophan 1©, which can also be found in the epoxidized form [24,25]. At the N-terminus
of the tryptophan, a γ,δ-unsaturated amino acid is incorporated 7© [26]. Common to all
derivatives is a unique 3-nitrotyrosine 3©, a building block not found in any other natural
product. The greatest variability is observed in the leucine building block 5©, which can
be oxidized to different oxidation levels at a terminal methyl group. In its original de-
scription, ilamycin was proposed to contain an aldehyde functionality [23], but structural
elucidation by NMR and X-ray crystallography showed that the aldehyde functionality
undergoes cyclization with the nearby amide bond [27–29]. Very recently, a wide range
of new ilamycins/rufomycins were described, differing mainly in the combination of dif-
ferent amino acid oxidation levels 5© and the N-prenyl substituent of 1© (alkene, epoxide,
diol) [27–29].
2.2. Discovery of the Cyclomarins
In 1999, the research groups of Fenical and Clardy reported the isolation of three
new anti-inflammatory cyclic peptides from extracts of a Streptomyces sp. collected in
Mission Bay, California [30]. These secondary metabolites from the strain CNB-982, called
cyclomarins (Cym) A−C, are structurally related to the rufomycins. Very similar amino
acid building blocks are incorporated, although in a different sequence. As in the ru-
fomycins, an N-prenylated tryptophan 1©(CymC) is a notable building block that can
also be epoxidized (CymA). However, in contrast to the rufomycins, in the cyclomarin
series, the tryptophan units are β-hydroxylated. At the N-terminus of the tryptophan, a
γ,δ-unsaturated amino acid is incorporated, not a linear one as found in the rufomycins,
but one that is branched and dimethylated 7©. One of the leucines is also oxidized at the δ
position 2©, at least in CymA and C, but at another position, as in the rufomycins. Most
obvious is the replacement of the unique nitrotyrosine by another aromatic amino acid,
syn-β-methoxyphenylalanine 4©.
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In 2010, the group of Mikami described the extraction of a new cyclomarin derivative
M10709 from clinically isolated Streptomyces sp. IFM 10,709 [31]. Although not all stere-
ogenic centers were determined properly, results revealed the compound was different
from cyclomarin C only by the replacement of the unsaturated amino acid 7© by valine. The
same structural motif was also found in a recently isolated metamarine in which a valine
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at position 3© replaced an alanine. The discovery of metamarine resulted from a larger soil
metagenome project undertaken to discover rufomycin/cyclomarin-like antibiotics [32].
3. Biosynthesis of Anti-Tubercular Cycloheptapeptides
Although the ilamycins/rufomycins were originally described in the early 1960s,
biosynthetic studies of these unusual cyclopeptides were reported only recently [27,33].
The first investigations of cyclomarins were conducted in 2008 by the Moore group [34,35],
while Brady et al. reported their results on metamarine biosynthesis in 2021 [32].
Although there are significant differences in the structures of these cycloheptapeptides,
they also have structural similarities and common biosynthetic features (Figure 2). A key
feature of the biosynthetic gene cluster is a gene encoding a heptamodular nonribosomal
peptide synthetase (NRPS). This NRPS is surrounded by a set of open reading frames (ORF)
that encodes tailoring enzymes (P450, oxygenases) and provides the required building
blocks for peptide synthesis. They contain the unusual amino acids N-prenyl-tryptophan (p-
Trp), 3-nitrotyrosine (Nitro-Tyr, ilamycins), as well as the unsaturated amino acids (2S,4E)-
2-amino-4-hexenoic acid (AHA, ilamycins) and (2S,3R)-2-amino-3,5-dimethylhexenoic acid
(ADH, cyclomarins). These building blocks are directly incorporated into the NRPS, while
oxidative tailoring enzymes encoded in the ORFs modify the protein-bound peptide during
synthesis. All biosyntheses start with the p-Trp 1© and end with a cyclization between 1©
and the C-terminal amino acids 7©.




Figure 2. Biosynthesis of rufomycins and (modified) cyclomarins; (a) Rufomycin gene cluster, (b) Cyclomarin gene cluster, 
(c) Metamarin gene cluster. 
3.1. Biosynthesis of the Ilamycins/Rufomycins 
A total of 20 genes are involved in the biosynthesis of these cyclopeptides (Figure 2a) 
[27,36]. Besides the gene encoding the NRPS, a second large gene encodes a type I polyke-
tide synthase (PKS), which is involved in AHA synthesis. (E)-4-Hexenic acid is obtained 
from AcCoA, and is further hydroxylated, oxidized (P450), and transaminated to AHA 
[33]. An N-prenyltransferase is responsible for the generation of the first amino acid of the 
sequence from tryptophan. The unusual 3-nitrotyrosine is obtained by P450-catalyzed ni-
trosation of tyrosine, and the NO required is provided by a nitric acid synthase from ar-
ginine [33]. Additional P450 cytochrome controls the final oxidation steps to create the 
different ilamycin family members [27]. 
3.2. Biosynthesis of Cyclomarins 
Although the cyclomarins are structurally related to the ilamycins, they are signifi-
cantly different, at least from a biosynthetic point of view (Figure 2b) [34,35]. In contrast 
to the ilamycins, the linear unsaturated amino acid AHA is replaced by the dimethylated 
derivative ADH, which has a completely different biosynthetic origin. While AHA is ob-
tained by a classical polyketide synthase, ADH is formed from valine and pyruvate [35]. 
Of the 23 ORFs of the biosynthetic gene cluster, several genes are responsible for ADH 
synthesis. Another significant difference is the β-OH functionality of the prenylated tryp-
tophan (p-Trp), which is found in all cyclomarins but not in the ilamycins and rufomycins. 
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3.1. Biosynthesis of the Ilamycins/Rufomycins
A total of 20 genes are involved in the biosynthesis of these cyclopeptides (Figure 2a) [27,36].
Besides the gene encoding the NRPS, a second large gene encodes a type I polyketide
synthase (PKS), which is involved in AHA synthesis. (E)-4-Hexenic acid is obtained from
AcCoA, and is further hydroxylated, oxidized (P450), and transaminated to AHA [33].
An N-prenyltransferase is responsible for the generation of the first amino acid of the
sequence from tryptophan. The unusual 3-nitrotyrosine is obtained by P450-catalyzed
nitrosation of tyrosine, and the NO required is provided by a nitric acid synthase from
arginine [33]. Additional P450 cytochrome controls the final oxidation steps to create the
different ilamycin family members [27].
3.2. Biosynthesis of Cyclomarins
Although the cyclomarins are structurally related to the ilamycins, they are signifi-
cantly different, at least from a biosynthetic point of view (Figure 2b) [34,35]. In contrast
to the ilamycins, the linear unsaturated amino acid AHA is replaced by the dimethylated
derivative ADH, which has a completely different biosynthetic origin. While AHA is
obtained by a classical polyketide synthase, ADH is formed from valine and pyruvate [35].
Of the 23 ORFs of the biosynthetic gene cluster, several genes are responsible for ADH
synthesis. Another significant difference is the β-OH functionality of the prenylated trypto-
phan (p-Trp), which is found in all cyclomarins but not in the ilamycins and rufomycins. Its
introduction is catalyzed by a tryptophan-β-hydroxylase, a dioxygenase, and occurs on the
protein-bound peptide in the early stages of the biosynthesis. In contrast, epoxidation of the
N-prenyl side chain by a P450 epoxidase occurs post-NRPS assembly. Gene inactivation of
the prenyltransferase eliminated the production of cyclomarin, indicating that p-Trp is the
initiator of the peptide assembly line and that the unmodified p-Trp is not a good substrate
for the first acceptor domain [34]. The β-hydroxylation must occur during the first two
steps of the peptide synthesis, since inactivation of the corresponding gene does not result
in the formation of a desoxycyclomarin but the formation of a dioxopiperazine called
cyclomarazine (Figure 3), containing only the first two amino acids of the biosynthesis.
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y and y B ere isolated fro the Strepto yces sp. B-982, together ith
Cy that as issing the N-methyl group on the δ-hydroxyleucine 2©. It is clear that
δ-hydroxylation by P450 leucine hydroxylase occurs faster than N-methylation, and trypto-
phan hydroxylation is essential for prolonging the peptide chain. If this hydroxylation does
not occur properly, the incompletely processed dipeptide is cleaved from the NRPS due to
ineffective processing by the next module. This reaction is a unique example in which a
megasynthetase can produce two different natural products of different sizes simply by
triggering the level of β-oxidation on the priming Trp unit. Notably, cyclomarazines do not
show significant biological activity.
The second major way in which cyclomarins differ from ilamycins is the incorpora-
tion of β-methoxyphenylalanine (MeOPhe) instead of nitrotyrosine. This amino acid is
obtained from a peptide-bound Phe via a P450-catalyzed β-hydroxylation followed by
O-methylation [35].
During their soil metagenome project, Brady et al. also investigated the biosynthesis
of metamarin. In this cyclomarin derivative, the unsaturated amino acid is replaced by
valine (Figure 2c) [32]. Another valine is incorporated instead of alanine 3©. Therefore, it is
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not surprising that the gene cluster is comparable to the cyclomarin cluster, and only the
genes responsible for ADH biosynthesis are missing.
4. Total Syntheses of Marine Cycloheptapeptides
The interesting biological properties and unusual building blocks of marine cyclohep-
tapeptides sparked the interest of synthetic chemists, and the syntheses of several different
amino acids and fragments have been reported in a recent review [37]. Therefore, they
will not be discussed in detail here, and the focus will be on the total syntheses of the
natural products.
4.1. Total Synthesis of Ilamycins/Rufomycins
To date, only one synthetic route has been described for ilamycins E1 and F by Guo
and Ye et al. [38]. In their highly convergent strategy, the ilamycins were synthesized
from two parts (1 and 2) that were linked between 1©and 7©to the macrocyclic lactam
(Scheme 1). The lower right tripeptide part 1 ( 1©– 3©) was prepared in five steps from
tryptophan, while the upper left tetrapeptide 2 ( 4©– 7©) required 13 steps from glutamic
acid. Final oxidation of the δ-hydroxyleucine 5© resulted in the described ilamycins.
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methylsilyl)ethoxycarbonyl (Teoc)-protected tryptophan methylester 3 was subjected to a 
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Saponification of the ester moiety of 4 and peptide coupling with N-methylated Leu-OMe 
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For the larger fragment 2, glutamic acid was converted into protected 8 (Scheme 3) 
according to a synthetic route developed during the synthesis of dysithiazolamide [40]. 
The glutamic acid was converted into the dimethyl ester and N-Boc protected before it 
was stereoselectively α-methylated at the sterically least-hindered ester moiety [41,42]. 
For the chemoselective reduction of the γ-ester 6, a second N-Boc-protecting group was 
introduced, and the sterically least-hindered ester functionality was reduced with DIBAL-
H. Silyl protection of the primary alcohol and subsequent mono-Boc deprotection yielded 
7. The methyl ester was saponified (to avoid α-methylation), and the Boc-amide was se-
lectively N-methylated to 8 with NaH/MeI. The free carboxylic acid 8 was converted into 
the corresponding benzyl ester. TMSOTf/NEt3 was used for selective cleavage of the N-
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t i f peptide fragment 1 was rather straightforward (Sch me ). 2
(Trimethylsilyl)ethoxycarbonyl (Teoc)-protected tryptophan methylester 3 was subjected to
a Pd-catalyzed N-tert-prenylation according to a protocol developed by aran et l. [ ].
Sa onification of the ester oiety of 4 an e ti e co ling ith - ethylated Leu- e
produced dipeptide 5, hich as further elongated to tripeptide 1.
For the larger fragment 2, glutamic acid was converted into protected 8 (Scheme 3)
according to a synthetic route developed during the synthesis of dysithiazolamide [40].
The glutamic acid was converted into the dimethyl ester and N-Boc protected before it
was stereoselectively α-methylated at the sterically least-hindered ester moiety [41,42].
For the chemoselective reduction of the γ-ester 6, a second N-Boc-protecting group was
introduced, and the sterically least-hindered ester functionality was reduced with DIBAL-
H. Silyl protection of the primary alcohol and subsequent mono-Boc deprotection yielded
7. The methyl ester was saponified (to avoid α-methylation), and the Boc-amide was
selectively N-methylated to 8 with NaH/MeI. The free carboxylic acid 8 was converted
into the corresponding benzyl ester. TMSOTf/NEt3 was used for selective cleavage of
the N-Boc-protecting group without affecting the OTBDPS group. The free amine could
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be coupled with Fmoc-protected alanine, and the C-terminal benzyl ester was cleaved by
catalytic hydrogenation to provide the free acid 9.
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according to a synthetic route developed during the synthesis of dysithiazolamide [40]. 
The glutamic acid was converted into the dimethyl ester and N-Boc protected before it 
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For the chemoselective reduction of the γ-ester 6, a second N-Boc-protecting group was 
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H. Silyl protection of the primary alcohol and subsequent mono-Boc deprotection yielded 
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TMSE ester. Boc-deprotection and peptide coupling produced dipeptide 12. Subsequent
Fmoc deprotection and coupling with 9 generated the linear tetrapeptide 2.
With the two major building blocks produced, ilamycin synthesis could proceed to
the final step (Scheme 4). Mild saponification of the methylester 1 and coupling with
Fmoc-deprotected 2 using (2-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hex-
afluorophosphate (PyAOP) [44] yielded 13 without significant epimerization. Global
deprotection with TBAF resulted in the linear heptapeptide, which was subjected to macro-
lactamization. While many peptide coupling reagents have been investigated, the best
results were obtained using pentafluorophenyl diphenylphosphinate (FDPP) [45]. As a
side product in addition to the expected cyclopeptide 14, the diphenylphosphinylated
ester was formed, which could directly be converted into 14 by treatment with K2CO3 in
methanol, providing an overall yield of 43% of the desired 14. Finally, only the primary
OH-functionality needed to be oxidized. Depending on the oxidation protocol, both il-
amycin E1 and F could be obtained. Ilamycin E1 was obtained as a single stereoisomer.
Notably, ilamycin F is also available on a gram scale via fermentation, but the derivative
E1, which is approximately 100-fold more potent, is not. Therefore, the authors developed
a protocol to convert ilamycin F into intermediate 14 by reducing the mixed anhydride,
permitting an interconversion of ilamycin F into ilamycin E1 [38].




Scheme 4. Synthesis of ilamycinE1 and F. 
4.2. Total Synthesis of Cyclomarins 
The amino acids present in the cyclomarins are slightly more complex than in the 
ilamycins, and various synthetic approaches have been undertaken to produce these 
building blocks and partial structures of cyclomarin [46]. These are covered in a recent 
review [37], and therefore only the routes applicable to the synthesis of cyclomarins and 
derivatives will be discussed here. 
The first synthesis of cyclomarin C was reported in 2004 by Yao and coworkers [47]. 
The unusual tert-prenylated β-hydroxy-tryptophan ① was obtained from indole deriva-
tive 15 (Scheme 5). This compound is available from indole via N-alkylation with ethyl-α-
bromo-propionate, subsequent α-methylation of the ester, LAH-reduction, and acetyla-
tion [48]. Formylation and a subsequent Horner–Wadsworth–Emmons reaction yielded 
α,β-unsaturated ester 16, which could be subjected to a Sharpless aminohydroxylation 
[49]. Moderate yield and enantioselectivity of the desired β-hydroxytryptophan deriva-
tive 17 was obtained. Unfortunately, no comment was made concerning the regioselectiv-
ity of the reaction. Silylation of the β-hydroxy group and selective transesterification of 
the acetate gave rise to primary alcohol 18, which could be oxidized to the aldehyde and 
methenylated via Wittig reaction. Finally, the Cbz-protecting group from 19 was removed 
selectively without affecting the generated double bond. Furthermore, the free amine was 
Fmoc-protected after saponification of the ester. The use of the Fmoc- or Alloc-protecting 
group is essential for the synthesis of cyclomarins because other protecting groups, such 
as Boc, cannot be removed later on without side reactions, such as the elimination of the 
β-hydroxy functionality [50]. 
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4.2. Total y thesis of yclo ari s
The a ino acids present in the cyclo arins are slightly ore co plex than i t
ila ycins, and various synthetic approaches have been ndertaken to r ce t se
building blocks and partial structures of c clo arin [46]. These are covered in a r t
revie [37], and therefore ly t e r tes lica le t t t sis f l ri s
derivatives ill be discussed here.
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The first synthesis of cyclomarin C was reported in 2004 by Yao and coworkers [47].
The unusual tert-prenylated β-hydroxy-tryptophan 1©was obtained from indole derivative
15 (Scheme 5). This compound is available from indole via N-alkylation with ethyl-α-
bromo-propionate, subsequent α-methylation of the ester, LAH-reduction, and acetyla-
tion [48]. Formylation and a subsequent Horner–Wadsworth–Emmons reaction yielded
α,β-unsaturated ester 16, which could be subjected to a Sharpless aminohydroxylation [49].
Moderate yield and enantioselectivity of the desired β-hydroxytryptophan derivative 17
was obtained. Unfortunately, no comment was made concerning the regioselectivity of
the reaction. Silylation of the β-hydroxy group and selective transesterification of the
acetate gave rise to primary alcohol 18, which could be oxidized to the aldehyde and
methenylated via Wittig reaction. Finally, the Cbz-protecting group from 19 was removed
selectively without affecting the generated double bond. Furthermore, the free amine was
Fmoc-protected after saponification of the ester. The use of the Fmoc- or Alloc-protecting
group is essential for the synthesis of cyclomarins because other protecting groups, such
as Boc, cannot be removed later on without side reactions, such as the elimination of the
β-hydroxy functionality [50].
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was selectively reduced in the presence of the tert-butyl ester using LiBH4, and the result-
ing primary alcohol was O-benzoylated to 23. Acidic cleavage of the tert-butyl ester, acti-
vation of the carboxylic acid, and reapplication of the Evans auxiliary A provided oxazol-
idinone 24. Deprotonation of 24 and stereoselective azidation produced azide 25. Catalytic 
hydrogenation in the presence of Boc2O resulted in the formation of the N-Boc-protected 
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e sy t esis of δ-hy r l i il i l 2© i t sit c fi i
f the γ-methyl group than in amino acid 5© in the ilamycins, was obtained by clas-
sical asymmetric synthesis using chiral auxiliary chemistry (Scheme 6). According to
Evans et al. [51], chiral oxazolidinone 21 was subjec ed as its titanium enolate in a Michael
addition to tert-butyl ac ylate to pr vide a good yield of 22 with high stereosel ctivity.
The imide was s lectively reduced i the presence of the tert-butyl ester using LiBH4, and
the resulting primary alcohol was O-benzoylated to 23. Acidic cleavage of the tert-butyl
ester, activation of the carboxylic acid, and reapplication of the Evans auxiliary A provided
oxazolidinone 24. Deprotonation of 24 and stereoselective azidation produced azide 25.
Catalytic hydrogenation in the presence of Boc2O resulted in the formation of the N-Boc-
protected amino derivative, which was saponified to the corresponding amino acid 26.
The desired N-methyl group was introduced by conversion of 26 into the corresponding
oxazolidinone 27, which was reduced using triethylsilane in presence of trifluoroacetic
acid. Subsequent cleavage of the Boc-protecting group required its reintroduction to 28.
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e sual -methoxyphenylalanine 4© t i
enylalanine 29, ich s t c r l i e
( che e 7). Oxygen functionality was introduced in o the β-position by subjecting 30
to a Wohl–Ziegler bromination, providing a 1:1 diastereomeric mixture of the desired -
bromo derivative [52]. According to Easton et al., treatment of the diastereomeric mixture
with AgNO3 in aqueous acetone produced the desired (2S,3R)-β-hydroxyphenylalanine
enantio- and diastereoselectively [53]. The stereochemical outcome can be explained by
a preferred conformation of the benzylic carbenium ion in the substitution step. The
best selectivities were obtained with the tert-butylamide. Subsequent O-methylation pro-
vided the methoxy derivative 31, converted into the N-Boc-protected amino acid 32 under
standard conditions.
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i ally, the unsaturated amino acid 7©was obtained via an asymmetric chelate enolate
Claisen rearrangement, develop d by Kazm ier et al. (Scheme 8) [54,55]. Trifluoroacetyl
(TFA)-protected glycine crotyl ester 33 was deprotonated a d converted into a chelated alu
minum ester enolate, which in the presence of quinidine underwent a [3,3]-sigm tropic re
arrangement to unsaturated amino acid 34 with good yield and enantioselectivity. Epim r
ization of the α-stereogenic center was avoid d by first converting 34 in o the Boc-protected
ester 35 and then, in a second step, into the corresponding phthal yl-pr tected deriv tive
36. A direct epimerization-free conversion (34 to 36) was not possible. Ozonolysis of th
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double bond and subsequent Wittig reaction produced protected amino acid 37, finally
converted into the Fmoc-protected acid 38.
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After the desired building blocks were created, the synthesis of cyclomarin C and
especially the best position for macrocyclization was investigated (Scheme 9) [47,56]. An
attempt to align the synthesis to the biosynthetic pathway and to cyclize the linear hep-
tapeptide precursor between the unusual tryptophan 1© and the unsaturated amino acid
7© failed. Although obtaining the linear peptide in a [3+3+1] peptide fragment coupling
strategy was straightforward, the final deprotection and ring closure yielded only trace
amounts of the desired product. The same was true for attempts to cyclize the linear
heptapeptide between the methoxyphenylalanine 4© and valine 5©. The trial to cyclize
between the sterically less demanding hydroxyleucine 2© and alanine 3© failed early in
the synthesis stage. All attempts to prolong the 1©, 2© dipeptide at the N-terminus failed.
Under the basic conditions for Fmoc-deprotection, spontaneous cyclization to the corre-
sponding diketopiperazine occurred, comparable to the previously discussed biosynthetic
side reaction, which resulted in the formation of the cyclomarazines. The ultimately suc-
cessful route was the cyclization between the unsaturated amino acid 7© and the C-terminal
N-methylleucine 6©. The linear heptapeptide was obtained via a [4+3]-coupling strategy.
An allyl ester was used as the C-terminal protecting group to avoid the basic reaction
conditions required for the saponification of the C-terminal ester, which caused problems
in previous cyclization attempts.
The desired tri- and tetrapeptide 39 and 40 were synthesized using classical peptide
coupling reactions and a combination of Boc- and Fmoc-protecting groups (Scheme 10).
Because of the acid lability of β-hydroxytryptophan, Fmoc had to be used after incorpo-
rating this building block into the growing peptide chain. The synthesis of the peptide
fragments was straightforward. An adequate yield of the tripeptide 39 was obtained
from N-Boc-valine 41 and N-methylleucine allyl ester 42. Boc-cleavage and coupling with
methoxyphenylalanine 32 produced 39, which was also N-deprotected to tripeptide 44.
Mar. Drugs 2021, 19, 446 12 of 27
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The synthesis of the tetrapeptide started with the coupling of protected δ-hy-
droxyleucine 28 with alanine allyl ester 45. After N-deprotection, the Fmoc-protected tryp-
tophan 20 was coupled using Bop-Cl/DIPEA [57]. Careful removal of the Fmoc-protecting 
group from 47 and EDC/HOBT-coupling with the unsaturated building block 38 provided 
tetrapeptide 40. Finally, the C-terminal allyl ester was cleaved under mild Pd-catalyzed 
conditions, and the two peptide fragments were ready for the fragment coupling. An ex-
cellent yield of 48 was obtained using EDC/HOAt, which proved more suitable than 
HOBT. Subsequent deprotection of the C- and the N-terminus and removal of the OTBS-
protecting group from the hydroxytryptophan provided the linear peptide precursor, 
which could be cyclized to 49 using PyBOP [58] under high dilution conditions and 
providing good yields. Finally, the benzoyl group had to be removed from the hy-
droxyleucine and cyclomarin C was purified via preparative HPLC. 
The second synthesis of cyclomarin C and the first for cyclomarin A were reported 
in 2016 by Barbie and Kazmaier [59]. Both natural products differ only in the oxidation 
state of the prenylated β-hydroxytryptophan unit ①, which is epoxidized in cyclomarin 
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The synthesis of the tetrapeptide started with the coupling of protected δ-hydroxyleucine
28 with alanine allyl ester 45. After N-deprotection, the Fmoc-protected tryptophan 20 was
coupled using Bop-Cl/DIPEA [57]. Careful removal of the Fmoc-protecting group from 47
and EDC/HOBT-coupling with the unsaturated building block 38 provided tetrapeptide
40. Finally, the C-terminal allyl ester was cleaved under mild Pd-catalyzed conditions, and
the two peptide fragments were ready for the fragment coupling. An excellent yield of
48 was obtained using EDC/HOAt, which proved more suitable than HOBT. Subsequent
deprotection of the C- and the N-terminus and removal of the OTBS-protecting group from
the hydroxytryptophan provided the linear peptide precursor, which could be cyclized to
49 using PyBOP [58] under high dilution conditions and providing good yields. Finally, the
benzoyl group had to be removed from the hydroxyleucine and cyclomarin C was purified
via preparative HPLC.
The second synthesis of cyclomarin C and the first for cyclomarin A were reported
in 2016 by Barbie and Kazmaier [59]. Both natural products differ only in the oxidation
state of the prenylated β-hydroxytryptophan unit 1©, which is epoxidized in cyclomarin A.
Therefore, a synthetic protocol was developed which gave access to both tryptophan deriva-
tives (Scheme 11). The synthesis started with a relatively new method for regioselective
tert-prenylation of electron-demanding indoles [60]. Using indole ester 50, a palladium-
catalyzed protocol delivered the required product 51 in almost quantitative yield. At
0 ◦C, no competitive n-prenylation was observed. In the next step, the activating ester
functionality needed to be replaced by iodine. Saponification of the ester and heating the
neat acid to 180 ◦C resulted in a clean decarboxylation to the N-prenylated indole, which
could be iodinated in almost quantitative yield. Iodide 52 was used as a key building
block for the synthesis of cyclomarin C, and after epoxidation, cyclomarin A. According
to Yokohama et al. [61], 52 was subjected to a Sharpless dihydroxylation, which unfortu-
nately demonstrated only moderate stereoselectivity. The best results were obtained with
(DHQD)2Pyr as chiral ligand, but the ee did not exceed 80 % [62]. Subsequent tosylation
of the primary OH-group and treatment with a base provided a good yield of the desired
epoxide 53. The iodides 52 and 53 were next converted into organometallic reagents and
reacted with a protected serinal. While the corresponding Grignard reagents provided
only moderate yields and selectivities, zinc reagents were found to be superior. According
to Knochel et al. [63,64], 52 was presumably converted into the indole–zinc–magnesium
complex 54a, which was reacted with freshly prepared protected serinal to give the de-
sired syn-configured 55a as a single diastereomer. In the case of the epoxyindole 53, a
slightly different protocol was used. To avoid side reactions during the metalation step,
53 was lithiated at −78 ◦C with n-BuLi and transmetallated with ZnBr2 [63,64]. The zinc
reagent 54b was directly reacted with the aldehyde to create 55b. According to NMR
and HPLC, only two diastereomers (ratio 9:1) could be detected following the Sharpless
dihydroxylation step. Obviously, the carbonyl addition also here was highly stereoselective.
Next, the secondary OH-functionality was TBS-protected under the assumption that a
primary OTBS-group could be removed selectively [65]. Notably, only a combination of
TBSOTf and lutidine gave the desired product 56a in high yield, while all other methods
failed and resulted in the decomposition of 55a. Interestingly, no complete conversion was
obtained for 55b, but the silyl ether 56b was obtained as a single stereoisomer. Obviously,
the undesirable diastereomer did not undergo silylation. Next, the primary silyl protecting
group was removed using NH4F in MeOH [66]. The free alcohols 57 had to be oxidized
to the desired carboxylic acids 59, which were found to be highly sensitive and not very
stable. By far, the best results were obtained using a two-step protocol beginning with a
Parikh–Doering oxidation [67]. The also very labile aldehydes were directly oxidized to the
corresponding methyl esters 58 with N-iodosuccinimide in MeOH [68]. These are stable,
can be stored under standard refrigeration, and should be saponified to the free acids 59
on demand.
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The third unusual a ino acid, β- ethoxyphenylalanine , could be obtained si i-
larly to the tryptophan building block  (Sche e 13). Protected (R)-serine 65 was reduced 
to the corresponding aldehyde, which was subjected to a chelate-controlled aryl- etal 
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to the corresponding aldehyde, which was subjected to a chelate-controlled aryl-metal
addition. The addition of phenylmagnesium bromide provided an acceptable yield but
only moderate diastereoselectivity (7:3). In contrast, in the presence of titanium salts, the
desired coupling product 66 could be obtained as a single diastereomer in enantiomerically
pure form. Further standard transformations yielded building block 32.
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an high stereoselectivity, and ester 71 was obtained after O-methylation. Ozonolysis
provided the desired aldehyde, which was subjected to a Wittig reaction. However, only
tiny amounts of the desired product could be obtained, even with a large excess of the
Wittig reagents, which also caused the chiral aldehyde’s epimerization. Better results
were obtained with a modified Julia–Kocienski reagent 72, normally used for (E)-selective
olefination [77]. Under these conditions, the desired unsaturated building block 73 could
be obtained almost epimerization-free. Saponification and change in the N-protecting
group provided amino acid 74.
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The hydrogenolysis of the Cbz-protecting group in dipeptide 76 was not a trivial
task. The reaction required an H2 pressure of 20 bar to proceed, and two equivalents of
HCl had to be added to avoid diketopiperazine formation. The hydrochloride salt was
directly coupled with the activated amino acid 32 in the presence of excess base. The next
steps were standard peptide couplings. BEP [78,79] was used to incorporate the sensitive
tryptophan building blocks 59. The Alloc protecting group was removed, Pd-catalyzed,
and the linear heptapeptide was cyclized using Yao’s protocol [47,56]. Finally, a two-step
protocol was needed to remove the two OTBS protecting groups separately, providing good
yields of cyclomarins A and C. Notably, cyclomarin D (desmethylcyclomarin C), missing
only the N-methyl group of the δ-hydroxyleucin, was also obtained by this protocol [80].
5. Syntheses of Cyclomarin Derivatives
Given the outstanding biological properties of the cyclomarins, it is not surprising
that multiple investigations have been undertaken to obtain modified cyclomarins for
SAR studies.
5.1. Mutasyntheses of Cyclomarin Derivatives
In studies of cyclomarin biosynthesis, Moore et al. identified an N-prenyltransferase
to prenylate tryptophan prior to loading the modified amino acid onto the NRPS [35].
A knockout mutant of Salinospora arenicola CNS-205 with a disrupted prenyltransferase
gene failed to produce cyclomarins but did produce desprenylcyclomarin C, although at
a 100-fold lower production rate. Obviously, tryptophan is not a good substrate for the
cyclomarin NRPS, but other N-alkylated tryptophans are well accepted [34]. These can be
obtained by simple alkylation of suitably protected tryptophan derivatives [81]. Feeding
the bacteria with methylated and propargylated tryptophan resulted in the production of
new cyclomarin derivatives CymM and CymP (Scheme 16).
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5.2. Se isyntheses of yclo arin erivatives
esearchers at ovartis observed that cyclomarin A might be a good candidate
for drug development since it kills not only Mycobacterium tuberculosis (Mtb) but also
the malaria parasite Plasmodium falciparum [82]. Thus, cyclomarin A is a rare example
of a natural product with two distinct and specific modes of action. The researchers
modified cyclomarin A, obtained by fermentation (Scheme 17) [83]. Ring-opening of the
prenylepoxide with 1,3-propanediamine provided amine 83, which was linked to sepharose
beads and processed by affinity chromatography to identify the target. Interestingly, 83
inhibits the growth of Mtb similarly to cyclomarin A [83,84]. Obviously, the epoxide of the
N-prenyl side chain is not responsible for the biological activity, at least against Mtb. In
contrast, replacing the terminal OH-group of the δ-hydroxyleucine 2© by an N-methylanilin
(84) caused a significant drop (>200 fold) in activity [83].
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6. Biological Activities and Mode of Action
6.1. Biological Activities of Ilamycins/Rufomycins
Both the ilamycins [14,15] and rufomycins [16,17] were isolated independently from
Streptomycetes in 1962 as new antibiotics, active against acid-fast bacteria, especially My-
cobacteria. Ilamycin A was reported to inhibit Mycobacterium 607 at 0.5 µg/mL, while
ilamycin B was less active (3 µg/mL). The rufomycins were reported to be highly active
against Mycobacterium smegmatis (RufA: 0.2 µg/mL, RufB: 0.5 µg/mL) and Mycobacterium
tuberculosis (RufA: 0.1–0.4 µg/mL, RufB: 1–5 µg/mL), also strains resistant to other an-
tibiotics such as streptomycin (SM), neomycin (NM), kanamycin (KM), and isonicotinic
acid hydrazide (INHA. The compounds are almost inactive against other Gram-positive
and Gram-negative bacteria, fungi, and yeasts. In addition, no significant toxicity was
observed on four-week-old mice by intraperitoneal injection (Ruf A, LD0 200 mg/kg and
LD100 360 mg/kg) [16].
Ma and Ju et al. recently isolated 12 new ilamycin analogs (IlaG-R) from a 200 L scale
culture of mutant Streptomyces atratus ZH16 ∆ilaR. The analogs demonstrated a slightly
different oxidation pattern compared to the previously isolated ilamycins [27,28]. Most
derivatives showed the same antibacterial activity as the other ilamycins and rufomycins
with MIC’s in the range of 1−2 µM against Mycobacterium tuberculosis, while the most active
examples thus far have been ilamycin E and J (Figure 5), both more active than rifampicin
used as a positive control.
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clize c s s c as Ila a IlaJ e strate reater acti it t a e -c ai
le ci e erivatives such as IlaB, IlaD, or IlaF (Figure 1). Oxidation of the prenyl side
chain did not affect activity. The nitro group on the tyrosine seems to play an important
role [27,28].
In 2020, Pauli et al. isolated eight new rufomycins (rufNBZ1-NBZ8) together with five
already known derivatives from the Streptomyces atratus strain MJM3502 [29]. Analogous
to the ilamycins, the most active derivatives contain a cyclic oxidized leucine such as
RufNBZ8 or the previously isolated Ruf I (Figure 6) with an MIC (M. tuber. HR37v) similar
to rifampicin (0.03 µM). Ruf I maintained activity against monoresistant, MDR, and XDR
strains, indicating that the Rufs most likely have a different molecular target than current
drugs used in TB therapy. Additionally, Ruf I retained its activity against strains from
the five global M. tuberculosis clades representative of clinical TB disease worldwide [87].
Especially interesting is its activity against M. abscessus, one of the more difficult-to-treat
mycobacteria [88].
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Detailed studies indicated that the ilamycins/rufomycins inhibit ClpC1, an enzyme
currently not targeted for TB treatment. ClpC1 is the ATP-dependent homolog of the
ClpC class of chaperone proteins present in M. tuberculosis [89] and is highly conserved
among mycobacteria. Unlike in many other bacteria, ClpC proteins are essential for the
viability of mycobacteria, especially M. tuberculosis. In this species, the strictly regulated
ClpC1 associates with the proteolytic domains, ClpP1 and ClpP2, and together they are
responsible for waste protein degradation within the cell [90]. Without functional ClpC1,
cellular protein degradation is reduced or stopped completely. Ruf I significantly decreases
the proteolytic capabilities of the ClpC1/P1/P2 complex while having no significant effect
on the ATPase activity of ClpC1 [87]. In this respect, it differs from ecumicin (Ecu), another
anti-tubercular cyclic peptide, which inhibits ClpC1 but stimulates ATPase activity. Details
of the binding topology and chemical mode of (inter)action of these cyclopeptides were
reported by Cho et al. [91]. The X-ray structure of a complex of the N-terminal helical
domain (NTD) of ClpC1 and Ruf I reveals distinct differences from the corresponding
ClpC1-NTD-cyclomarin A structure. Surprisingly, the complex structure shows that the
epoxide moiety of Ruf I is opened and covalently bound to ClpC1-NTD via the sulfur atom
of a methionine in the binding pocket [92,93].
Although the anti-tubercular activity is the most prominent effect of ilamycins/rufomycins,
certain derivatives show some anti-cancer activities, while others do not. IlaC (Ruf I) was
found to be preferentially cytotoxic towards triple-negative breast cancer (TNBC) cell lines,
the most aggressive subtype of breast cancer with poor prognoses. IlaC can induce Bax/Bcl-
2-related caspase-dependent apoptosis and inhibit migration and invasion in TNBC by
suppressing IL-6-induced STAT3 phosphorylation [94]. IlaE, but not IlaF, decreases cell
viability, inhibits G1/S cell cycle progression, and promotes apoptosis in the TNBC cell
lines HCC1937 (IC50 14.2 µM) and MDA-MB-468 (IC50 24.5 µM). It promotes apoptosis
via activation of endoplasmic reticulum (ER) stress, increasing CHOP expression and
down-regulating the expressi f a ti-a optotic protein Bcl-2 [94].
6.2. Biological Activities of Cyclomarins
Fenical and Clardy et al., who isolated the cyclomarins A−C in 1999, reported that
the major metabolite cyclomarin A (CymA) showed anti-inflammatory activity in vivo and
in vitro [30]. Lat ron, Pittayakhajonwut et al. reported that CymC shows a ti-malarial
activity against multidrug-resistant Plasmodium falciparum strains (IC50 0.25 µM) as well as
anti-TB activity (MIC: 0.1 µM) [95]. No significant activity was observed against cancer
cells or Candida albicans (IC50 > 50 µM). Schmitt et al. at Novartis investigated the mode
of action in detail [83]. CymA was found to bind specifically and with a high affinity to
ClpC1 and did not interfere with ATP binding by the two ATPase domains of ClpC1. The
antimycobacterial activity of cyclomarin derivatives correlates well with binding to ClpC1.
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For example, amino alcohol 83 (Scheme 17) demonstrated high affinity (MIC: 0.1 µM),
while no binding was observed for the inactive amine 84. The hydroxy functionality on
leucine 2© is clearly important for binding, but not the epoxide.
The exact binding of CymA toward the NTD of ClpC1 was determined by high-
resolution co-crystal structure analysis [84]. The overall sequence identity of ClpC1 from
various Mycobacterium species is close to 95%, but the NTD of mycobacterial ClpC1 is
100% conserved. This phenomenon explains why all tested mycobacteria were found
to be sensitive to CymA. Based on the structure of the complex, several mutations were
engineered into ClpC1, which showed reduced CymA binding in vitro. The ClpC1 mutants
were overexpressed in mycobacteria and two showed resistance to CymA, providing clear
evidence that ClpC1 is the target of CymA.
Using NMR and small-angle X-ray scattering, Schanda and Fraga et al. demonstrated
that arginine-phosphate binding to the ClpC1 NTD induces millisecond dynamics [96].
Cyclomarin binding to this domain specifically blocks these dynamics. Based on these
results, a proposed mechanism of action involves the cyclomarin-induced restriction of
ClpC1 dynamics, which modulates the chaperone enzymatic activity leading eventually to
cell death [96]. Very recently, Mogk et al. showed that CymA activates an ATP-driven bac-
terial AAA+ protease (e.g., ClpP) and that cell death is induced by uncontrolled proteolytic
activity of these enzymes [97].
However, anti-TB activity is not the only interesting feature of the cyclomarins. Schmitt
et al. showed that CymA is a potent growth inhibitor of Plasmodium falciparum, and its
molecular target, diadenosine triphosphate hydrolase (PfAp3Aase), was identified by
chemical proteomics [82]. CymA is a specific inhibitor of the plasmodial enzyme (IC50:
0.004 µM) but not of the closest human homolog hFHIT (IC50 > 10 µM). Co-crystallization
experiments demonstrated a unique inhibitor binding mode. One molecule of CymA binds
a dimeric PfAp3Aase and prevents the formation of the enzyme-substrate complex. These
results validate PfAp3Aase as a new drug target for the treatment of malaria. Thus, CymA
is a rare example of a natural product with two distinct and specific modes of action.
Unfortunately, CymA as a natural product lacks satisfactory pharmacokinetic proper-
ties, making it challenging for optimization into an (orally) bioavailable drug. Therefore,
Kazmaier et al. tried to simplify the complex structure of the cyclomarins without losing
significant biological activity. Because the β-hydroxytryptophan unit 1© is the most critical
building block, they removed the hydroxy functionality completely, and the desoxycyclo-
marins obtained were further modified on the prenyl side chain of 1©, the hydroxylated
leucine 2©, the β-methoxyphenylalanine 4© and the unsaturated amino acid 7© [37,73,85,86].
Selected biological data are summarized in Table 1.
Certain modifications at R1 were well-tolerated (series 87). Reduction to an isopropyl
group (87c) provides an especially promising simplification retaining antimycobacterial
activity. In general, manipulations at this position do not result in dramatic effects on
potency measured against Mtb and Pfalcp. Interestingly, the methyl group in 87d is an
appropriate balance between reducing synthetic complexity and loss of activity.
Results obtained for the modifications at R2 were consistent with the data obtained
by X-ray structure analysis [82]. In the case of Pfalcp, where this residue is completely
buried between the target and the ligand scaffold, large changes are not accepted. How-
ever, it is important that removing the terminal methyl group in the cis position of the
γ,δ-unsaturated side chain led to an equivalent or even slightly improved activity. Fur-
ther simplifications, however, are not advisable, as they lead to dramatic activity losses,
which are seen in the comparison of 87a and 88a. In contrast, the anti-TB activity was
not influenced.
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Table 1. Biological data of cyclomarins and selected desoxycyclomarins.
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Removal of the methyl group at R3 led to a decrease in potency against both pathogens
(89). This result was indeed expected for the Mtb target ClpC1-NTD [96]. This group
interacts well with the target, which is also closely packed with the indole motif of the
tryptophan core. However, it is not yet clear why deletion of this methyl residue impairs
activity towards Pfalcp.
Modifications of R4 on β-methoxyphenylalanine 4© were also well tolerated (90). The
amino- and azido-derivatives 90a and 90b were equipotent to cyclomarin C, and the nitro
compound 90c was even twice as active. Only in the case of bromo derivative 90d was a
significant drop in activity observed.
7. Conclusions
The ilamycins/rufomycins and the cyclomarins are highly interesting marine cyclo-
heptapeptides characterized by their incorporation of unusual amino acids. The natural
products are produced by Streptomyces sp. and show potent activity against a range of
mycobacteria, including multidrug-resistant strains of Mycobacterium tuberculosis. No signif-
icant activity has been observed towards other Gram-positive and Gram-negative bacteria
or fungi.
The cyclomarins are also very potent inhibitors of Plasmodium falciparum, the organism
that causes malaria. Biosynthetically, the cyclopeptides are obtained via a heptamodular
NRPS that directly incorporates some of the nonproteinogenic amino acids, while oxida-
tions at certain positions allow the compounds to proceed to protein-bound biosynthetic
intermediates. Cyclized ilamycins/rufomycins are obtained by oxidative post-NRPS cy-
clization of leucine 7©, the last introduced amino acid in the biosynthesis. A wide range
of derivatives can be obtained by fermentation, while bioengineering also allows the mu-
tasynthesis of derivatives, especially cyclomarins. Other derivatives are accessible by
semisynthesis or total syntheses, reported for both natural product classes. Some of these
derivatives were used to identify the biological targets of these peptides. The anti-TB activ-
ity results from the binding of the peptides to the N-terminal domain (NTD) of the protease
ClpC1, causing cell death by the uncontrolled proteolytic activity of associated enzymes.
Diadenosine triphosphate hydrolase (PfAp3Aase) was found to be the active target of
the cyclomarins in Plasmodia, and this enzyme might be a good candidate for the treatment
of malaria. SAR studies of natural and synthetic derivatives on the ilamycins/rufomycins
and cyclomarins indicate which parts of the molecules can be simplified/modified without
losing activity towards either target.
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